Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Vaccinal effect of HIV-1 antibody therapy.

Naranjo-Gomez M, Pelegrin M.

Curr Opin HIV AIDS. 2019 Jul;14(4):325-333. doi: 10.1097/COH.0000000000000555.

PMID:
30973419
2.

Neutrophils are essential for induction of vaccine-like effects by antiviral monoclonal antibody immunotherapies.

Naranjo-Gomez M, Lambour J, Piechaczyk M, Pelegrin M.

JCI Insight. 2018 May 3;3(9). pii: 97339. doi: 10.1172/jci.insight.97339.

3.

Effects of Low-Level Laser Therapy in Orthodontic Patients on Immediate Inflammatory Response After Mini-Implants Insertion: A Preliminary Report.

Yanaguizawa MS, Suzuki SS, Martinez EF, Suzuki H, Pelegrin MC, Garcez AS.

Photomed Laser Surg. 2017 Jan;35(1):57-63. doi: 10.1089/pho.2015.3959. Epub 2016 Nov 3.

PMID:
27813716
4.

Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play.

Lambour J, Naranjo-Gomez M, Piechaczyk M, Pelegrin M.

Emerg Microbes Infect. 2016 Aug 17;5(8):e92. doi: 10.1038/emi.2016.97. Review.

5.

Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?

Pelegrin M, Naranjo-Gomez M, Piechaczyk M.

Trends Microbiol. 2015 Oct;23(10):653-665. doi: 10.1016/j.tim.2015.07.005. Review.

PMID:
26433697
6.

The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs.

Bossis G, Sarry JE, Kifagi C, Ristic M, Saland E, Vergez F, Salem T, Boutzen H, Baik H, Brockly F, Pelegrin M, Kaoma T, Vallar L, Récher C, Manenti S, Piechaczyk M.

Cell Rep. 2014 Jun 26;7(6):1815-23. doi: 10.1016/j.celrep.2014.05.016. Epub 2014 Jun 5.

7.

[Vaccine-like effects of antiviral monoclonal antibodies: a novel therapeutic perspective?].

Pelegrin M, Gros L, Piechaczyk M.

Med Sci (Paris). 2013 May;29(5):457-60. doi: 10.1051/medsci/2013295005. Epub 2013 May 28. French. No abstract available.

8.

Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies.

Nasser R, Pelegrin M, Plays M, Gros L, Piechaczyk M.

Blood. 2013 Feb 14;121(7):1102-11. doi: 10.1182/blood-2012-06-432153. Epub 2012 Dec 20.

PMID:
23264590
9.

Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody.

Nasser R, Pelegrin M, Michaud HA, Plays M, Piechaczyk M, Gros L.

J Virol. 2010 Oct;84(19):10169-81. doi: 10.1128/JVI.00568-10. Epub 2010 Jul 7.

10.

A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy.

Michaud HA, Gomard T, Gros L, Thiolon K, Nasser R, Jacquet C, Hernandez J, Piechaczyk M, Pelegrin M.

PLoS Pathog. 2010 Jun 10;6(6):e1000948. doi: 10.1371/journal.ppat.1000948.

11.

An NF-kappaB-dependent role for JunB in the induction of proinflammatory cytokines in LPS-activated bone marrow-derived dendritic cells.

Gomard T, Michaud HA, Tempé D, Thiolon K, Pelegrin M, Piechaczyk M.

PLoS One. 2010 Mar 8;5(3):e9585. doi: 10.1371/journal.pone.0009585.

12.

Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis.

Santoro L, Boutaleb S, Garambois V, Bascoul-Mollevi C, Boudousq V, Kotzki PO, Pèlegrin M, Navarro-Teulon I, Pèlegrin A, Pouget JP.

J Nucl Med. 2009 Dec;50(12):2033-41. doi: 10.2967/jnumed.109.066993. Epub 2009 Nov 12.

13.

Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons.

Pouget JP, Santoro L, Raymond L, Chouin N, Bardiès M, Bascoul-Mollevi C, Huguet H, Azria D, Kotzki PO, Pèlegrin M, Vivès E, Pèlegrin A.

Radiat Res. 2008 Aug;170(2):192-200. doi: 10.1667/RR1359.1.

PMID:
18666820
14.

Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.

Ychou M, Azria D, Menkarios C, Faurous P, Quenet F, Saint-Aubert B, Rouanet P, Pèlegrin M, Bascoul-Mollevi C, Guerreau D, Saccavini JC, Mach JP, Artus JC, Pèlegrin A.

Clin Cancer Res. 2008 Jun 1;14(11):3487-93. doi: 10.1158/1078-0432.CCR-07-4698.

15.

Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice.

Gros L, Pelegrin M, Michaud HA, Bianco S, Hernandez J, Jacquet C, Piechaczyk M.

J Virol. 2008 Feb;82(3):1339-49. Epub 2007 Nov 21.

16.
17.

Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.

Gros L, Dreja H, Fiser AL, Plays M, Pelegrin M, Piechaczyk M.

J Virol. 2005 May;79(10):6272-80.

18.

Monoclonal antibody-based genetic immunotherapy.

Pelegrin M, Gros L, Dreja H, Piechaczyk M.

Curr Gene Ther. 2004 Sep;4(3):347-56. Review.

PMID:
15384948
19.

Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation.

Perez N, Bigey P, Scherman D, Danos O, Piechaczyk M, Pelegrin M.

Genet Vaccines Ther. 2004 Mar 23;2(1):2.

20.

Monoclonal antibody 667 recognizes the variable region A motif of the ecotropic retrovirus CasBrE envelope glycoprotein and inhibits Env binding to the viral receptor.

Dreja H, Gros L, Villard S, Bachrach E, Oates A, Granier C, Chardes T, Mani JC, Piechaczyk M, Pelegrin M.

J Virol. 2003 Oct;77(20):10984-93.

Supplemental Content

Loading ...
Support Center